DARWIN EU delivers realworld evidence across Europe diseases population us performance medicines enables EMA national competent authority European medicine regulatory network use data whenever needed throughout lifecycle medicinal product Data Home EMA established coordination centre provide timely reliable evidence use safety effectiveness medicine human use including vaccines real world healthcare database across European Union EUThis capability called Data Analysis Real World Interrogation Network DARWIN EU Expression Interest Call open Data Partners information found  Latest News European Health Data Space DARWIN EU connect European medicine regulatory network European Commissions European Health join data network Open Call DPs described document welcome expression interest data custodian Data Network strategic priority DARWIN EU expand scope network generation new evidence supporting DARWIN EU deliver DARWIN EU delivers realworld evidence across Europe diseases population us performance medicines enables EMA use data whenever needed throughout lifecycle  DARWIN EU support regulatory decisionmaking by establishing expanding catalogue observational data source use medicine regulation providing source highquality validated real world data uses safety medicines addressing specific question carrying highquality noninterventional studies including developing scientific protocols interrogating relevant data source interpreting reporting study results range approved healthcare database enabling distributed data access via DARWIN EU evolve expand time former HMAEMA Big Data Task Force originally recommended developing DARWIN EU creation DARWIN EU feature EMAHMA Big Data Steering Group workplan European medicine agency network strategy  information Timelines February  EMA selected service provider Erasmus University Medical Center Rotterdam deliver DARWIN EU following call tender   service provider will set DARWIN EUs operational process governance structures run study data DARWIN EU support EMA scientific committee downstream decisionmakers decisionmaking support establishment EHDS  EMA expects DARWIN EU fully operational stage DARWIN EU routinely support evaluation work EMAs scientific committee  Organisations  payer may make use DARWIN EU longer term Figure  Overview DARWIN EU timeline  Project initiation Select service provider deliver DARWIN EUCoordination Centre Establish DARWIN EU Advisory Board Support EDHS pilot  DARWIN EU establishment Define governance structures contract model process Run early study support EMA committee Provide first catalogue real world data source standard analysis Establish connectivity EHDS  Developing using DARWIN EU Launch publiclyavailable DARWIN EU website Work established data permit authority Test business process access analyse healthcare data Run study support EMA committee  Full operation mode Conduct study answer question support EMA scientific committee DARWIN EUfully operational involvement data partner medicine regulator  Leverage EU Health Data Space Increase geographical coverage scope regulatory us healthcare data DARWIN EU Related content External link Related document List item First published  EMA List item First published  EMA List item First published  Last Updated  December  Disclaimer content website responsibility DARWIN EU Coordination Centre cannot interpreted reflecting view European Medicines Agency European Medicines Regulatory Network    European Medicines Agency right reserved Certain part licensed condition European Medicines Agency Data Home EMA established coordination centre provide timely reliable evidence use safety effectiveness medicine human use including vaccines real world healthcare database across European Union EUThis capability called Data Analysis Real World Interrogation Network DARWIN EU Expression Interest Call open Data Partners information found  Latest News European Health Data Space DARWIN EU connect European medicine regulatory network European Commissions European Health join data network Open Call DPs described document welcome expression interest data custodian Data Network strategic priority DARWIN EU expand scope network generation new evidence supporting DARWIN EU deliver DARWIN EU delivers realworld evidence across Europe diseases population us performance medicines enables EMA use data whenever needed throughout lifecycle  DARWIN EU support regulatory decisionmaking by establishing expanding catalogue observational data source use medicine regulation providing source highquality validated real world data uses safety medicines addressing specific question carrying highquality noninterventional studies including developing scientific protocols interrogating relevant data source interpreting reporting study results range approved healthcare database enabling distributed data access via DARWIN EU evolve expand time former HMAEMA Big Data Task Force originally recommended developing DARWIN EU creation DARWIN EU feature EMAHMA Big Data Steering Group workplan European medicine agency network strategy  information Timelines February  EMA selected service provider Erasmus University Medical Center Rotterdam deliver DARWIN EU following call tender   service provider will set DARWIN EUs operational process governance structures run study data DARWIN EU support EMA scientific committee downstream decisionmakers decisionmaking support establishment EHDS  EMA expects DARWIN EU fully operational stage DARWIN EU routinely support evaluation work EMAs scientific committee  Organisations  payer may make use DARWIN EU longer term Figure  Overview DARWIN EU timeline  Project initiation Select service provider deliver DARWIN EUCoordination Centre Establish DARWIN EU Advisory Board Support EDHS pilot  DARWIN EU establishment Define governance structures contract model process Run early study support EMA committee Provide first catalogue real world data source standard analysis Establish connectivity EHDS  Developing using DARWIN EU Launch publiclyavailable DARWIN EU website Work established data permit authority Test business process access analyse healthcare data Run study support EMA committee  Full operation mode Conduct study answer question support EMA scientific committee DARWIN EUfully operational involvement data partner medicine regulator  Leverage EU Health Data Space Increase geographical coverage scope regulatory us healthcare data DARWIN EU Related content External link Related document List item First published  EMA List item First published  EMA List item First published  Last Updated  December  Disclaimer content website responsibility DARWIN EU Coordination Centre cannot interpreted reflecting view European Medicines Agency European Medicines Regulatory Network    European Medicines Agency right reserved Certain part licensed condition European Medicines Agency Data AboutWho Involved involved DARWIN EU ha multiple actors     Data Partners DARWIN EU collaborates data partner help generate realworld evidence used scientific evaluation regulatory decisionmaking Data partner partner access raw data inhouse remotely ownership public contract thirdparty agreement commercial license Data partner enable DARWIN EU use data scientific study executing analytic packages provide analysis result DARWIN EU Coordination Centre accordance data protection governancerules information see page Coordination Centre ha key function DARWIN EU CC provides structure developing managing network data partners including training process study methods evaluating eligibility performing studies monitoring data quality CC also responsible implementing operating step  feasibility request study final delivery study report EMA result integrated within EU regulatory decision making process addition Coordination Centre responsible methodological development DARWIN EU directed instructed EMA interact relevant initiatives Erasmus University Medical Center Rotterdam wa selected contractor public tendering procedure published June  setup Coordination Centre EMA information see page European Medicines Agency responsible providing leadership direction setting standard DARWIN EU contracting instructing overseeing Coordination Centre monitoring performance question raised EU Medicines Regulatory Network requiring additional evidence support regulatory decisionmaking EMA coordinate definition research question define requesting body study objective possible study design option study population exposures outcome statistical measures information communicated Cordination Centre feasibility assessment Based feasibility assessment EMA consultation Cordination Centre decide relevance conducting study specify eligibility criterion database included identify relevant database define evidentiary standard applied study eg data quality EMA process result analysis report specific studies feeding result decisionmaking appropriate support establishment DARWIN EU ha set EMA EU Medicines Regulatory Network EU Medicines Regulatory Network includes EMA encompassing scientific committee working parties national competent authority NCAs Member States European Economic Area EEA European Commission operation DARWIN EU need additional realworld evidence identified within EU Medicines Regulatory Network support regulatory activity submitted discussed EMA Organisations Interactions EMA organisations institution project take place improve infrastructure methodological standard operational process DARWIN EU network interaction could take place with example EHDS DARWIN EU key user need fully integrated use service provided EHDS ongoing EU national project scope DARWIN EU relevant quality transformation maintenance analysis realworld datasets including European networking initiative EHDEN project European platform registry European Reference Networks ERNs ha established registry platform rare diseases ENCePP network integration continuously updating good methodological practice pharmacoepidemiology identification data source registration studies regulatory authority third countries learn experience integrate learning governance methodological aspects Last Updated  March  Disclaimer content website responsibility DARWIN EU Coordination Centre cannot interpreted reflecting view European Medicines Agency European Medicines Regulatory Network    European Medicines Agency right reserved Certain part licensed condition European Medicines Agency Data AboutCoordination Centre Coordination Centre EMA working Erasmus University Medical Center Rotterdam to establish theDARWIN EUCoordination Centre support work build distributed data network conduct scientific study answer research question supporting regulatory decisionmaking EMAs scientific committee  maintain catalogue real world data source use regulatory context metadata DARWIN EU Coordination Centre key user future  contract establish Coordination Centre wa awarded Erasmus University Medical Center Rotterdam following call tender service provider published June  group Department Medical Informatics leading Establishment Operational Phase DARWIN EU Coordination Centre Organisational Structure DARWIN EU CC exists run study within data partner network overseen Study Network Operations pillars respectively pillar able execute study onboard Data Partners using tool such code protocols created Development pillar within infrastructure ha created Technology pillar Technology pillar also responsible producing necessary project resources website service desk overall operation DARWIN EU overseen Management pillar guidance Advisory Boards Leadership Erasmus MC Executive Director Technology Pillar Lead Erasmus MC Oxford University Deputy Director Development Pillar Lead Erasmus MC Deputy Director Study Operations Pillar Lead Synapse Research Management Partners Management Pillar Lead Erasmus MC Network Operations Pillar Lead Additional Members core team  Development Pillar Colead  MSc Analytics Team Colead  Study Operations Colead  Technology Pillar Colead  Management Pillar Colead  Management Team Lead addition large team data scientists epidemiologist programmer working Coordination Centre Erasmus MC subcontractors Contributing Organisations Organisation Department Medical Informatics Erasmus MC Description Erasmus University Medical Center largest eight university medical center Netherlands Department Medical Informatics chaired Prof dr ir Peter Rijnbeek interdisciplinary research group within Erasmus MC study new method acquiring representing processing managing data knowledge health care biomedical science ha developed land marking infrastructure software distributed analysis electronic health records Health Data Science research line Prof Rijnbeek leading  EHDEN mission group produce clinically actionable insight observational health data enabling datadriven healthcare Improved interoperability data necessary prerequisite mission Learn Organisation Clinical Investigation Translational Science NDORMS University Oxford Description Clinical Investigation Translational Science division Botnar Research Centre NDORMS University Oxford includes Clinical Trial Design Medical Statistics Health Data Science sections Health Data Science section led Prof Daniel PrietoAlhambra includes multidisciplinary team  staff student expertise data sciences engineering epidemiology real world evidence Learn at Organisation Synapse Research Management Partners Description Synapse firm specialized high quality management complex research development project biomedical sector Synapse partner national international organisations public private pharmaceutical biotechnology companies research institutes academia hospitals etc Synapse ha track record research project highly innovative open innovation public private partnerships large with several million Euros funding distributed built collaboration several institutions internationally oriented with broad expertise project funded European Commission Learn  Organisation Description IQVIA leading global provider advanced analytics technology solutions clinical research service health sector across globe IQVIA creates intelligent connection across aspect healthcare analytics transformative technology big data resource extensive domain expertise IQVIA delivers powerful insight speed agility enabling life science industry customer accelerate clinical development commercialization innovative medical treatment enabling government ass improve public health population management leading improved patient outcomes approximately  employees IQVIA conduct operation  countries Learn  Organisation Hyve Description Hyve company provides professional service open source software specialize field cancer genomics translational data warehousing real world data analytics research data management customer include majority top  pharmaceutical companies major academic medical center US Europe well biobanks registry patient organization throughout world Learn Organisation Odysseus Data Services Inc Description Odysseus established realworld evidence RWE solution provider enabling standardized systematic analytics observational data scale Odysseus providing customer Software Data Engineering Data Science solution supporting largescale RWE generation Odysseus active OHDSI contributor multiple key initiative working groups including design development OHDSI platform ATLASWebAPI ARACHNE ATHENA OMOP CDM standards curating maintaining OMOP standard vocabulary well development OHDSI analytical method HADES OHDSI distributed network research Odysseus created ARACHNE platform goal linking multiple distributed life science healthcare organization single network enable standardized federated analytics observational data Learn Data Partners CC ha set agreement growing list Data Partners create distributed network data sources information Data Partners found page Last Updated  May  Disclaimer content website responsibility DARWIN EU Coordination Centre cannot interpreted reflecting view European Medicines Agency European Medicines Regulatory Network    European Medicines Agency right reserved Certain part licensed condition European Medicines Agency Data AboutPrinciples  Policies Principles  Policies Table content Data Protection DARWIN EU Coordination Center CC executes study distributed data network using federated approach analytical code shared data partner aggregated study result shared CC privacybydesign approach additional measure added example minimum cell count comply local governance rules data partner setup includes information procedure information study execution found  latest version Record Processing Activities ROPA found below information also see  Cookie Policy DARWIN EU Coordination Center websitewe use cooky enablethe technical functioning thiswebsiteIn addition consent it use cooky collect browsing experience website enables u tocollect anonymous statistic help u improve website services information see website Conflict Interest study analysis conducted DARWIN EU shall conducted accordance principle scientific independence set According ENCePP scientific independence mean that primary purpose study shall generate evidence potential scientific public health importance promote use medicinal product specific outcome design research shall aim minimising potential bias financial commercial institutional personal interest particular outcome study ie result interpretation level organisations initiating funding study coordinating study entity andor researchers conducting study shall influence decision scientific aspect study direction including data collection analysis interpretation dissemination study results relevant definition principle set shall also applied Related content Related document List item First published  EMA List item First published  Last Updated  March  Disclaimer content website responsibility DARWIN EU Coordination Centre cannot interpreted reflecting view European Medicines Agency European Medicines Regulatory Network    European Medicines Agency right reserved Certain part licensed condition European Medicines Agency Data AboutEuropean Health Data Space European Health Data Space DARWIN EU connect European Commissions  initiative promote better exchange access different type health data need use case medicine regulator decisionmakers drive DARWIN EUs development DARWIN EU also contributes developing EHDS joint action deliver European principle secondary use health data known  Acting early flagship pathfinder EHDS DARWIN EU enable exchange healthcare data use healthcare delivery policymaking research across Europe fully complying data protection requirements EHDS HealthDataEU Pilot Recently EHDS Pilot Project wa initiated run till September  project led French Health Data Hub HDHa French organisation aim ensure easy unified transparent secure access health data improve quality care support patients Multiple consortium involved EHDS pilot EU agency EMA included national platform international research infrastructures consortium aim answer European Commissions call project concretely test EHDS practice creating network data platform European level conducting crossborder research use cases provide recommendation future EHDS pilot project create first European network secondary use data projects containing metadata search portal data access request portal central services Within network project leader able querymetadata catalogue node ask data access several node single data application form EMA authorised participant consortium partner within EHDS pilot project EMAs use case thrombosis see below aim leverage DARWIN EU among platforms DARWIN EU EHDS pilot two complementary synergetic project secondary use health data EMA Use Case EMAs use case aim investigate natural history coagulopathy use antithrombotic agent COVID patient person vaccinated SARSCoV study ha previously conducted via EMA Framework Contract result study may used benchmarking  important use case test wayDARWIN EU integrated EHDS future Six specific objective study presented increasing levelof complexity chosen data partner considering capability data hold important evaluate data different node combined considering data available Common Data Model CDM via DARWIN EU data available node native format wa also clarified CDM prerequisite becoming node EHDS pilot future data sources registriesfor example converted CDM objective see different data source combined single study meaningful way information Last Updated  March  Disclaimer content website responsibility DARWIN EU Coordination Centre cannot interpreted reflecting view European Medicines Agency European Medicines Regulatory Network    European Medicines Agency right reserved Certain part licensed condition European Medicines Agency Data AboutWebinars DARWIN EU multistakeholder information webinar Date  LocationOnline    Amsterdam time CET Event summary EMA organised multistakeholder information webinar to introduce DARWIN EU recently appointed Coordination Centre highlight opportunity collaboration answer stakeholder questions Video recording Documents Last Updated  March  Disclaimer content website responsibility DARWIN EU Coordination Centre cannot interpreted reflecting view European Medicines Agency European Medicines Regulatory Network    European Medicines Agency right reserved Certain part licensed condition European Medicines Agency Data AboutCareers Careers Coordination Centre regularly ha open position example Programmers Epidemiologists Data Scientist join DARWIN EU team posted page Feel free contact Coordination Centre email like information email address protected spambots need JavaScript enabled view it Last Updated  March  Disclaimer content website responsibility DARWIN EU Coordination Centre cannot interpreted reflecting view European Medicines Agency European Medicines Regulatory Network    European Medicines Agency right reserved Certain part licensed condition European Medicines Agency Data DataData Network Data Network strategic priority DARWIN EU expand scope network generation new evidence supporting benefitrisk decision making EU Regulatory Network collaboration EMA Scientific Panel Coordination Centre shall seek identify new data partner data source integrate new infrastructure technique network data partners data partner enable DARWIN EU use data scientific studies provide analysis result DARWIN EU Coordination Centre accordance data protection rules part data network directly Data Permit Authority shown figure below DARWIN EU expected bring board minimum ten data source every year following requirement defined candidate data sources Data source collecting health data routinely representative different type realworld data term data elements setting primary  secondary care population origin eg electronic health care records claims Data source collectively provide broad geographical coverage Data source containing patientlevel data unique patient identifier linking record relating given patient Medicines prescribed dispensed identifiable quantity eg doses package size date allowing calculate cumulative dos duration use linked individual unidentifiable patient Clinical event formally coded accurate date linked individual unidentifiable patient Data already converted planned converted common data model access torealworld healthcare data source ashospitals primary care health insurance registriesandbiobanks Data Sources selected consultation DARWIN EU Advisory Board andfollowing prioritisation criterion below Continuous data collection at least annual data updates lag time le six month data availability analysis capture health outcome medicine prescribing dispensing Data converted Observational Medical Outcomes Partnership OMOP common data model current list Data Sources N Data Partner Data Source Country  Centre hospitalier universitaire de Bordeaux France  University Oxford United Kingdom  University Tartu Estonia  Consorci Mar Parc de Salut Barcelona PSMar together Fundacio Institut Hospital del Mar dInvestigacions Mediques IMIM Spain  Mieur Implementation Exploitation BV Netherlands  IQVIA Solutions BV Germany  IQVIA Solutions BV Belgium  Integraal Kankercentrum Nederland Netherlands  Fundacion Instituto Universitario para la Investigacion en Atencion Primaria de Salud Jordi Gol Gurina IDIAPJGol Spain  Finnish Institute Health Welfare Finland Finland  Clinical Academic Center Egas Moniz Health Alliance Portugal  Croatian Institute Public Health Croatia  University Oslo Norway  Semmelweis University Hungary  Health Data Hub France  University Oxford United Kingdom  Unidade Local de Sade de Matosinhos Portugal  FISABIO Spain  Agencia Espaola de Medicamentos Productos Sanitarios AEMPS Spain  Danish Health Data Registries Danish Health Data Registries Onboarding progress Denmark Related document List item First published  Last Updated  April  Disclaimer content website responsibility DARWIN EU Coordination Centre cannot interpreted reflecting view European Medicines Agency European Medicines Regulatory Network    European Medicines Agency right reserved Certain part licensed condition European Medicines Agency Data DataWhy join network join data network role DARWIN EU Data Partner DPs part DARWIN EU network maintain relationship CC realised two different ways DPs active study participant coauthor results DPs onboarded eligible participate study undertaken DARWIN EU mean that feasibility assessment ha completed may invited study and agreeing participate run centrallydeveloped code return aggregated result CC integration reporting However DPs data provider running common analytics returning results expert database contribute aspect study including design quality control dissemination results therefore believe suitably experienced DPs able optin multiple role study including scientific epidemiological expertise reportpublication development also important necessary capacity building DARWIN EU scale facilitate completion study parallel operational phase expected participating DPs coauthor publication resulting corresponding studies DPs receive DARWIN EU training provide periodic training workshops part offered via remote learning environments DPs aware latest best practice data use management study development method tools Onboarded DPs expected actively participate thriving DARWIN EU community allow exchange experience opportunity continuing improvement growth benefit DARWIN EU DPs Working benefit EMA EMRN generation realworld evidence critical medicine regulation European level example diseases patient populations use safety effectiveness medicines including vaccines throughout lifecycle medicinal product Supporting decisionmaking use safety effectiveness medicines wide range stakeholder benefit patient healthcare professional health technology assessment body pharmaceutical industry Participation highimpact publication derived study undertaken DARWIN EU Assurance scientific independence freedom decline studies respect institution approval procedures Facilitated scientific collaboration connection peer learning becoming part thriving academicmedicalregulatory network community Increased external visibility DPs data expanding opportunity participate studies joint research project grant proposal beyond DARWIN EU helping longterm sustainability DP Boosted opportunity participate international study larger regulatory impact provide invaluable resource prepare respond future healthcare crisis pandemics Improved interoperability understanding data enhancing data partner internal decisionmaking processes potential propagate learning inside institution enhance procedure generally improve underlying healthcare systems Added possibility auditingrefiningvisualising data open source tooling understanding data set better including integrative analyses revealing potential flaw continued improvement Increased transparency analysis reproducibility enabling study easily transposed data source multiplied impact eg publications Increased speed performing studies improved performance accelerated research monthsyears weeks allowing DPs undertake study le time le resources Access training platform data standardisation quality control analytics Coordination Centre Exposure collaborative experience worldclass expert realworld evidence generation using OMOP CDM Last Updated  March  Disclaimer content website responsibility DARWIN EU Coordination Centre cannot interpreted reflecting view European Medicines Agency European Medicines Regulatory Network    European Medicines Agency right reserved Certain part licensed condition European Medicines Agency Data DataHow join network join data network Open Call DPs described document welcome expression interest data custodian Europe wishing considered candidate DP DARWIN EU include primary secondary care data sources claim databases biobanks etc open data source Open Call instrument facilitate level playing field interested institution participate DARWIN EU aim compile relevant information candidate Data Partners support decision making EMA determine DPs formally invited join initiative express interest process simple DPs interested need provide information data sources Expression Interest EoI form moment form Excel spreadsheet accessible here Potential DPs download form complete offline form duly completed must sent authorised representative ie person institution authority submit applications following email address email address protected spambots need JavaScript enabled view it happens submission Expression Interest Upon receipt CC acknowledge receipt email reply sender Expression Interest correctly received checked CC completeness consistency scope Expressions Interest deemed incomplete inconsistent scope rejected stage candidate informed correspondingly within two week receipt date Rejected submission due lack completeness consistency resubmitted correcting EoI EoIs become part list interested potential DPs list reviewed CC EMA least twice year corresponding EoIs received following date every year th April st October Although deemed ordinary cutoff dates CC EMA reserve right reviewing application point time depending need network forthcoming studiesFollowing request EMA CC may announce termination Open Call DPs review process examine Expressions Interest consider factor type data size geographical representativeness added value network perceived data quality governance procedures coverage specific populations past experience studies potential intention convert data status mapping OMOP CDM etc result short list DPs approached Final decision short list rest EMA considering current future need studies Shortlisted DPs may approached CC discus outstanding question CCEMA experts directly invited initiate formal onboarding process consist several step finish signature agreement CC see  signal official participation DARWIN EU Data Partner important note guarantee given candidate DP regard selection effective incorporation DARWIN EU onboarding process successfully completed agreement CC ha signed Conversely submission EoI nonbinding candidate DPs may withdraw selection process longer interested received EoIs remain list interested potential DPs unless applicant express wish removed email address mentioned above shortlisted review round Additionally Expression Interest form allows DPs explicitly agree information submit automatically included public EMA Metadata Catalogue data sources increasing discoverability researcher conduct scientific studies FAQ Open Calls No considered candidate DP first step submit Expression Interest Yes unless duly justified case appropriate justification included information contained EoI primarily used purpose evaluating candidacy formally become DARWIN EU Data Partner access associated Data Protection Notice  Additionally providing consent response specific question EoI form potential DP agree EoI information used populate EU Metadata Catalogue EMA initiative help improve data discoverability transparency Catalogue intended public use read associated Data Protection Notice No continuously open call please bear mind cutoff date th April st October review selection No CC may contact clarify certain aspect datasets EoI invite initiate formal onboarding process latter successfully completed agreement signed DARWIN EU DP onboarding process consists several quality technical check ensure readiness DARWIN EU studies plus explanation term condition participation agreement legal provision apply relationship CC duration vary   months ordinarily No onboarding process ha successfully completed agreement CC ha signed Related document List item First published  List item First published  Last Updated  December  Disclaimer content website responsibility DARWIN EU Coordination Centre cannot interpreted reflecting view European Medicines Agency European Medicines Regulatory Network    European Medicines Agency right reserved Certain part licensed condition European Medicines Agency Data Methods Methods DARWIN EU implement necessary paradigm shift delivery reliable evidence regulatory decisionmaking utilisation safety effectiveness medicinal product throughout lifecycle DARWIN EU significantly scale number study number databases also substantially bringing cost study make DARWIN EU groundbreaking venture RealWorld Evidence generation ambitious endeavour cannot result simply scaling traditional approach used today implement DARWIN EU must remove obstacle currently prevent exploitation existing data required speed quality need setup procedure tool federated study execution compliant governance rule privacy regulations requires improve interoperability data develop standardised analytics develop tool host artefact created study reused future studies information topic see menu item left Last Updated  March  Disclaimer content website responsibility DARWIN EU Coordination Centre cannot interpreted reflecting view European Medicines Agency European Medicines Regulatory Network    European Medicines Agency right reserved Certain part licensed condition European Medicines Agency Data Study Execution Study Execution DARWIN EU Studies executed using socalled federation approach shown figure below approach Data Partners distributed data network keep full control data patient level data shared Coordination Centre CC aggregated study results Study Execution process divided following Phases Exploration Initiation Implementation Execution Dissemination Exploration Phase EMA interacting Coordination Centre explore feasibility study request respect preferred design available data resources timelines  Study Request Research question originate EU Regulatory Network need information support authorisation monitoring medicinal product subsequent decisionmaking may include example query incidence prevalence disease European population drug utilisation pattern specific product collection additional data potential safety signal evaluation association drug clinical outcome assessment effectiveness risk minimisation measure envisaged future research question may also originate stakeholder European Commission European Centre Disease Prevention Control ECDC Health Technology Assessment HTA body payers requester together EMA prepares Feasibility Assessment Form containing short title request regulatory background motivating query important information understanding query product andor eventsoutcomes interest objective proposal study design relevant design consideration choice data source methodological aspects choice study design supported providing range possible analysis different level complexity Routine repeated Offtheshelf Complex implication term database needed timelines  Feasibility Assessment Coordination Centre performs feasibility assessment EMA review aim ass feasibility study based relevant factor concerned study including example number exposed patients number events time period minimum duration exposure considered time lag occurrence event feasibility implementing study design available database criterion depending study feasibility assessment principle use information already available CC characteristic database via precalculated Data Dashboards relevant information necessary simple data analysis could performed relevant database available example simple count number patient exposed medicinal product experienced clinical event defined time period data analysis may performed limited number database Coordination Centre undergo quality assurance process performed full study result feasibility analysis next included Feasibility Assessment Form recommendation regarding conduct study decision initiate study formally made EMA Initiation Phase contractual agreement setup selected Data Partners Study Team formed Conflicts Interest procedure applied Contractual Agreements Upon green light conduct study Coordination Centre responsible contractual agreement onboarding Data Partners study standardised work order initiated DARWIN EU CC indicates agreed timeline budget study data partner sign standard work order agreement specifies activities budget timelines Team Formation level involvement study team strongly depend Study Type ie simple shelf study may run near automatically fast review step small team complex study larger team may proposed Study Operations team consist data scientists epidemiologists clinical domain expert responsible Evidence Generation Evidence Synthesis team completed Data Stewards participating Data Partners work secured collaboration space Documentation assessment Conflicts Interest Potential investigator assigned DARWIN EU study shall requested declare existing direct indirect interest pharmaceutical company term defined  detail DARWIN EU Conflict Interest Procedure found section EMA review submitted form approve team composition Implementation Phase study artefact created Study Outline Study Protocol Cohort Definitions Study Package Study Outline agreement reached EMA DARWIN EU CC conduct DARWIN EU study Study Outline Form completed describing aspect as Study Team Data Sources Choice study type related study design including methodological aspects governance board approval timelines completed Study Outline Form next submitted EMA approval Study Outline Form approved EMA protocol DARWIN EU study generated Study Outline approved signedoff EMA archived DARWIN EU CC study specific project file Study Protocol Development agreement reached EMA DARWIN EU CC Study Outline Study Protocol generated following  Upon completion Draft Study Protocol Study Protocol need approved EMA Study Protocol approved signedoff EMA study protocol archived DARWIN EU CC study specific project file Next final study protocol uploaded Kickoff meeting Following finalisation protocol prior study execution kickoff meeting organised Study Project ManagerPrincipal Investigator study team member explain protocol agree roles responsibility timeline study execution Governance Board Approval Protocol approval study site often required comply local implementation relevant law directive various European states data custodian responsible protocol approval local governance board prior study execution specified Framework Contract Data Partner Cohort Construction Assessment needed phenotype target outcome cohort work across included data source generated facilitated  addition  latter provides indepth characterisation phenotype definitions secular trend time standard well orphan source code not included source code may interest cohort participants characterisation Study Package Creation analysis pipeline study type described within used need instantiated cohort interest right parameter setting obtain Study Package example study estimate incidence prevalence health outcome Package used parameter set according protocol study initiation test run analytics performed subset data source simulated set patient quality control check performed test passed final package released private repository version controlled  package distributed data partner local execution agains OMOP CDM Execution Phase Data Partners execute Study Package OMOP CDM review aggregated results includes applying quality check study result data privacy check assure aggregated data shared compliant local governance procedures Execution Iterations data partner locally execute analytics OMOPCDM review approve aggregated result returning Coordination Centre Sometimes multiple execution iteration performed additional fine tuning code base needed service desk available study execution support Quality Control study result data source checked made available team Digital Research Environment Dissemination Phase start result locked timestamped reproducibility transparency Dissemination Phase evidence synthesised report result dashboards potentially publications study artefact retained Evidence Synthesis result data source combined produce table figure needed report Digital Research Environment amount effort Evidence Synthesis strongly depend study complexity ie le effort offtheshelf routine repeated study effort complex studies pooling databasespecific result prespecified per protocol including rulesdiagnostics precluding inclusion database use metaanalytic approach combine dataspecific estimates result reviewed conclusion formed context prior knowledge relevant Dashboard Instantiation study executed OMOPCDM large amount study result generated many data sources Therefore dashboard form web application made simplify exploration results uploaded study result easily combined single folder dashboard instantiated web application either made publicly available necessary made available behind security layer Reporting Study Results study team writes report andor publication study report written accordance Guideline good pharmacovigilance GVP module VIII EMA guidance ENCePP final study reports uploaded  Study finding preferably considered publication open access publication guided Uniform Requirements Manuscripts Submitted Biomedical Journals Writing Editing Biomedical Publication International Committee Medical Journal Editors  Retention closure study generated documents used analytics study result archived enable reproducibility Last Updated  March  Disclaimer content website responsibility DARWIN EU Coordination Centre cannot interpreted reflecting view European Medicines Agency European Medicines Regulatory Network    European Medicines Agency right reserved Certain part licensed condition European Medicines Agency Data Data Interoperability Data Interoperability Increasing productivity reliable Real World Evidence generation requires standardisation automation analytical processes cannot done without standard representation data Full interoperability data needed respect structure syntactic interoperability coding system semantic interoperability using Common Data Model CDM OMOP Common Data Model DARWIN EU using OMOP CDM ismaintained OHDSI global community OHDSI community also ha active led Erasmus MC OMOP CDM provides syntactic semantic interoperability Syntacticly OMOP CDM relational database consisting table demographic clinical event Standardised Clinical Data information care setting Standardised Health System health economics Standardised health economics record derived clinical table Standardized derived elements Standardized metadata semantic layer provided Standardized vocabularies ha populated OMOP standard concept relationships standardized vocabulary centrally maintained distributed semantic interoperability especially important Europe myriad terminology system languages Tools available data standardisation data quality data analysis commercially public domain see example  OMOP CDM designed federated querying analytics whereby application run locally data partner site aggregated result shared privacybydesign approach compliant data protection requirements OMOP CDM proven model largescale observational health studies ha used including study informed regulatory decisionmaking large number European database already available OMOP CDM format example EHDEN project investing M privatepublic funding standardising health data OMOPCDM Innovative Medicines Initiative  adoption OMOP CDM growing Europe formed Quality Control Mechanisms part Data Partner DP onboarding DARWIN EU Coordination Centre CC ass quality data DARWIN EU data quality package aligned EMA benefit interoperable data model dat use standardised tooling extract objective data quality metrics purpose currently using two packages R Package support onboarding process Data Partner DP DARWIN EU Data Network extract statistic DPs OMOP CDM instance produce Word document goal onboarding report provide insight completeness transparency quality performed Extraction Transform Load ETL process readiness data partner onboarded DARWIN EU data network participate DARWIN EU studies onboarding report consists three sections Clinical Data section report data table counts data density followup period length date ranges Vocabulary Mapping section especially important data quality show concept mapping coverage per domain top mappedunmapped codes Finally Technical Infrastructure section give insight readiness DP execute studies overview query timings installed package system information CdmOnboarding run onsite DP extract data directly OMOP CDM precalculated table OHDSI R package OMOP CDM characterisation resulting Word document required annex main Onboarding Document delivered upon first onboarding However CdmOnboarding required run every CDM refresh result shared CC inspection R package maintained OHDSI community performs set  standardised check populated OMOP CDM instance goal evaluate observational data quality systematic transparent way quality check organized according us system category context represent strategy assessing data quality DQD contains  check defined within framework systematically executed relevant table field OMOP CDM Examples check executed DQD are doe tablefield exist populated doe right data type cdmField cdmDataType isRequired doe field follow standard semantic interoperability isStandardValidConcept genderspecific diagnosisprocedure associated correct person gender gender measurement value within extreme range valueLow valueHigh Clair Blacketer Frank J Defalco Patrick B Ryan Peter R Rijnbeek Increasing trust realworld evidence evaluation observational data quality Journal American Medical Informatics Association Volume  Issue  October  Pages  External link Last Updated  March  Disclaimer content website responsibility DARWIN EU Coordination Centre cannot interpreted reflecting view European Medicines Agency European Medicines Regulatory Network    European Medicines Agency right reserved Certain part licensed condition European Medicines Agency Data Standardised Analytics Standardised Analytics DARWIN EU Coordination Centre CC ha set maximise value efficiency realworld evidence regulator stakeholder Europe mind recognised Standardised Analytics needed speed evidence generation whilst preserving quality reproducibility transparency proposed research Standardised Analytics enabled use OMOP Common Data Model OMOP CDM ha several advantages risk different implementation study design would case common protocol shared translated code programmer site Differences study outcome therefore related data instead study implementation Standardised Analytics made Study Type reused specific study defining study parameters example Drug Utilisation Analytical tool made parameter Population Drugs Interest Standardised Analytics produce standardised help EMA committee streamline assessment results Standardised Analytics tested validated following agreed Quality Assurance Processes test data set OMOP CDM format CC developing Catalogue Standard Data Analyses accommodate requested study designs study DARWIN EU deliver grouped anticipated level complexity Offtheshelf Complex Complex OffTheShelf Complex Studies repeated periodically prespecified regularity eg yearly called Routine Repeated Analyses development Common Analytics driven initial list study Establishment Phase DARWIN EU find current version catalogue discussion stakeholder  catalogue maintained regularly Catalogue Standard Data Analyses Catalogue Standard Data Analyses list various analysis currently supported CC Offtheshelf study mainly characterisation question executed generic protocol includes disease epidemiology example estimation prevalence incidence health outcome defined time period population groups drug utilization study population patient level Study Types Patientlevel characterisation classified shelf Study Design Cohort analysis Participants Patientlevel characterisation study include one cohorts people newly diagnosed  prespecified conditions amount data visibility diagnosis record conditions previous year or previous history Additional eligibility criterion could apply follows incorporated sensitivity analyses Additional restrictions could apply based sociodemographics eg people aged  older time diagnosis Additionally people competing differential diagnosis could also excluded eg people rheumatoid arthritis history psoriatic arthritis could excluded minimise misclassification Followup Participants followed date new diagnosis index date earliest following loss followup end data availability prespecified time period eg  year index date death Analyses Details discussed programming pipelines likely patientlevel characterisation include Automated largescale characterisation including recorded baseline characteristic available data index date based codes classified condition medical history medicines use procedures Prespecified patientlevel characteristic andor index date based preexisting code list definition eg history type  diabetes Charlson comorbidity index Prespecified patientlevel characteristic andor index date based concept descendant previously validated algorithm available Incidence rates prespecified outcomes within prespecified time period eg  year Prognosis  progression prespecified outcome within prespecified time eg cumulative incidence certain event mortality within  years diagnosis Standard care description including n  receiving prespecified list medicines devices procedures combination within prespecified time window diagnosis Study Types Patientlevel DUS analysis classified shelf studies Patientlevel DUS offer possibility include populationlevel DUS analysis part analysis Study Design New drugs user cohort Participants Patientlevel DUS analysis include one cohorts incident drug user least  year data visibility use drugdrug class previous year Additional eligibility criterion could apply follows Source population could restricted specific subpopulation certain sociodemographic clinical features eg people diagnosis rheumatoid arthritis start take diseasemodifying antirheumatic drug DMARD Additional restrictions could apply per product label indication study aims eg people aged  older time therapy initiation Followup Participants followed date therapy initiation index date earliest loss followup end data availability death Patients might censored time discontinue treatment switch alternative therapy Outcomes following outcomes obtained potentially stratified prespecified criterion age bands sex calendar year month prespecified criteria New drug user cohorts patientlevel characteristic index date Indication where available Initial dosestrength as prescribeddispensed therapy initiation available Cumulative use within prespecified time period eg  year based number prescription dosestrength Treatment duration Count repeated prescription prespecified time period eg  year Analyses Patientlevel DUS analytics include Largescale characterisation patientlevel feature based codeconcept descendants including sociodemographics comorbidity previous medicines use time history year andor month previous index date Frequency  indications based prespecified list diagnosis recorded therapy initiation where available Reporting minimum p median p maximum initially prescribed dispensed dosestrength where available Reporting minimum p median p maximum cumulative use within prespecified time period eg  year Reporting minimum p median p maximum treatment duration Reporting minimum p median p maximum number repeated prescription index drug prespecified time period eg  year Study Type Populationlevel DUS analysis classified shelf studies Study Design Populationlevel cohort Participants Populationlevel analysis include entire source population least time typically  year data visibility available start study period Additional eligibility criterion apply follows Analyses incidence drug use exclude prevalent user drugdrug class index date andor previous washout year study population could restricted specific subpopulation certain sociodemographic eg age  older history prespecified clinical features eg people prior diagnosis rheumatoid arthritis cases minimum followup requested eg treatment pattern analysis Outcomes following outcomes obtained potentially stratified prespecified criterion age bands sex calendar year month Populationbased incidence rate use drugdrug class calendar time Periods could calendar days weeks months quarter years Populationbased prevalence use drugdrug class given time point point prevalence within given time period period prevalence Periods could calendar days weeks months quarter years Followup Followup start prespecified calendar time point predefined index date  eg st January st month continue prespecified time period typically week month quarter year Analyses Populationlevel DUS analysis use analytical pipeline Populationlevel descriptive epidemiology study see separate subsection Incidence rate number new user with prespecified washout numerator total population personyears except prevalent users denominator Prevalence calculated number user prevalent new whole source population specific time point ie point prevalence specific time window ie period prevalence may stratified sociodemographics eg age band sex andor calendar period Additional criterion eg disease severityduration may need considered integrated prespecified future studies Study Types Populationlevel descriptive epidemiology classified shelf studies Study Design Populationlevel cohort Participants Populationlevel analysis include entire source population least time typically  year data visibility available index date Additional eligibility criterion apply follows Analyses disease incidence exclude patient previousprevalent history disease index date andor previous washout year andor previous history source population could restricted specific subpopulation certain sociodemographic clinical features eg people aged  index date Outcomes following outcomes obtained potentially stratified prespecified criterion age bands sex calendar year month prespecified criteria Populationbased incidence diseasecondition or group diseasesconditions given time point time stratified calendar period Populationbased prevalence disease or group diseasesconditions given time point eg prespecified date andor time eg stratified month year Followup Followup start prespecified calendar time point predefined index date  eg st January st given month continue prespecified time period typically week month year Analyses Incidence rate number newly diagnosed people numerator total population satisfying study eligibility criteria denominator Prevalence calculated number people diagnosis prevalent new whole source population specific date point prevalence window time period prevalence stratified sociodemographics eg age band sex andor calendar period criterion eg disease severityduration may need considered integrated future studies Complex study requiring development customisation specific study designs protocols analytics phenotypes includes study safety effectiveness medicine vaccines Motivation Although new user cohort preferred prevalent user design desirable instances particularly recently marketed medicine compared existing heavily used active comparator many new user recently launched previous user existing active comparator medicine lead situation new user new medicine use active comparator scarce potentially non representative desired target population user new drug Prevalent user cohort study used recent year study potential effect medicine like ACE inhibitor alphablockers SARSCoV infection andor COVID severity   Study Types Prevalent user active comparator cohort study classified complex analyses Study Design Prevalent user cohorts Participants least two cohorts including cohort prevalent user least one drugmedicinal product investigation target cohort cohort prevalent user least one drugmedicinal product active comparator comparator cohort Typically prevalent user cohort defined previous use targetcomparator medicine specific time period prespecified duration Followup Participants cohort followed specific index date different date treatment initiation Based previous examples typically calendar date eg st March  Two possibility analysis offered fixed followup analysis followup continue death loss followup prespecified time period eg  years regardless treatment duration treatment analysis followup continue treatment cessation death loss followup Outcomes One study outcome prespecified based previous DARWIN EU algorithm newly developed validated ones addition long list negative control outcome assessed known causal association drugs medicinal products study Analyses Details discussed programming pipelines new user cohort analysis include Largescale characterisation participant target comparator cohorts including feature available data index date Largescale propensity score LSPS estimated probability exposure target cohort conditional available covariates available data prevalence  LSPS estimated using Lasso regression Different new user cohorts LSPS estimated using information available index date case prevalent user date therapy initiation different previously specified date Incidence rates outcome interest target comparator cohort LSPS matching stratification inverse probability weighting Diagnostics Covariate balance plot produced depicting standardized mean differences target comparator cohort available covariates x axis propensity score matchingstratificationweighting y axis see Figure  illustrative example Equipoise plot distribution propensity score stratified target v comparator cohort see Figure  illustrative example Analyses conducted insufficient data based prespecified minimum detectable rate ratio eg MDRR Optional addition two above residual confoundingsystematic error available estimation based number negative control outcomes significantly associated exposure interest Rate Ratios Hazard Ratios  confidence interval estimated using Poisson Cox model respectively comparing target v comparator reference cohort LSPS matching stratification inverse probability weighting Optionally calibrated RR HR estimated empirical calibration using negative control outcome Study Types New user active comparator cohort study classified complex analyses Study Design New user cohorts Participants least two cohorts including cohort new user least one drugmedicinal product investigation target cohort cohort new user least one drugmedicinal product active comparator comparator cohort Typically new user cohort exclude previous user either cohort previous year well people  year data visibility inclusion Followup Participants cohort followed therapy initiation date index date Two possibility analysis offered fixed followup analysis followup continue death loss followup prespecified time period eg  years regardless treatment duration treatment analysis followup continue treatment cessation death loss followup Outcomes One study outcome prespecified based previous DARWIN EU algorithm newly developed validated ones addition long list negative control outcome assessed known causal association drugs medicinal products study Analyses Details discussed programming pipelines new user cohort analysis include Largescale characterisation participant target comparator cohorts including feature available data index date Largescale propensity score LSPS estimated probability exposure target cohort conditional available covariates available data prevalence  LSPS estimated using Lasso regression Incidence rates outcome interest target comparator cohort LSPS matching stratification inverse probability weighting Diagnostics Covariate balance Equipoise plot distribution propensity score stratified target v comparator cohort Analyses conducted insufficient data based prespecified minimum detectable rate ratio eg MDRR Optional addition two above residual confoundingsystematic error available estimation based number negative control outcome significantly associated exposure interest Rate Ratios Hazard Ratios  confidence interval estimated using Poisson Cox model respectively comparing target v comparator reference cohort LSPS matching stratification inverse probability weighting Optionally calibrated RR HR estimated empirical calibration using negative control outcome Study Types Selfcontrolled case risk interval study classified complex analyses Study Design Selfcontrolled case risk interval SCRI Participants like SCCS SCRI study include one cohorts people suffer specified safety eventgroup events least records Additional eligibility criterion could apply based sociodemographics clinical characteristics Followup SCRI design us prespecified control interval relative exposure typically vaccination date control time control interval exposure must defined priori therefore predefine studyspecific followup pre andor postexposure control interval periods participant followedobserved prespecified control interval immediately afterduring exposure medicinal product Similar SCCS specified control interval either pre andor postexposure period considered baseline unexposed whilst treatment episodes exposed Outcomes One study outcome prespecified based previous DARWIN EU algorithm newly developed validated ones Ideally outcome acute presentation clear accurate diagnosis date addition long list negative control outcome assessed known causal association drugs medicinal products study Analyses Details discussed programming pipelines SCRI include Largescale characterisation SCRI participant time diagnosis including recorded feature available data index date based SNOMED codes Prespecified patientlevel characteristic andor diagnosis based preexisting cohort definition eg history type  diabetes Charlson comorbidity index Prespecified patientlevel characteristic andor diagnosis based concept descendant previously validated algorithm available Incidence rates prespecified control interval exposed time Diagnostics Eventexposure independence histogram time event date end observation individual censored uncensored plotted ass potentially eventdependent observation time Analyses conducted insufficient data based prespecified minimum detectable rate ratio eg MDRR Optional addition two above residual confoundingsystematic error available estimation based number negative control outcome significantly associated exposure interest Incidence rate ratio  confidence interval estimated using conditional Poisson regression models comparing exposed v control interval period Adjusted incidence rate ratio  confidence interval calculated adjustment age seasonality Optionally calibrated incidence rate ratio estimated empirical calibration adjusted incidence rate ratio based observed systematic error Study Types Selfcontrolled case series classified complex C analyses Study Design Selfcontrolled case series SCCS Participants SCCS include one cohorts people suffer specified safety eventgroup event least records hence denomination case series Additional eligibility criterion could apply based sociodemographics clinical characteristics Followup predefine followup period according exposure history Typically participant SCCS followed time preexposure exposed postexposure medicinal product Sometimes washout imposed beginning exposure period Pre postexposure period considered baseline unexposed whilst treatment episodes exposed washout period disregarded accounted analyses See Figure  illustration analyses first event considered participant minimise biases followup censored first event Outcomes One study outcome prespecified based previous DARWIN EU algorithm newly developed validated ones Ideally outcome acute presentation clear accurate diagnosis date addition long list negative control outcome assessed known causal association drugs medicinal products study Analyses Details discussed programming pipelines SCCS include Largescale characterisation SCCS participant time diagnosis index date including recorded feature available data date based SNOMED codes Prespecified patientlevel characteristic index date based preexisting cohort definition eg history type  diabetes Charlson comorbidity index Prespecified patientlevel characteristic index date based concept descendant previously validated algorithm available Incidence rate exposed unexposed time Diagnostics Eventexposure independence histogram time event date end observation individual censored uncensored plotted ass potential eventdependent observation time Analyses conducted insufficient data based prespecified minimum detectable rate ratio eg MDRR Optional addition two above residual confoundingsystematic error available estimation based distribution result negative control outcome analysis Incidence rate ratio  confidence interval estimated using conditional Poisson regression models comparing exposed v baseline period Adjusted incidence rate ratio  confidence interval calculated adjustment age seasonality Optionally calibrated incidence rate ratio estimated empirical calibration adjusted incidence rate ratio based observed systematic error Study Type considered complex epidemiological study require bespoke modelling intervention like public health restriction calculation population andor patientlevel disease epidemiology estimates analysis take form interrupted time series analyse impact intervention eg public health restriction changes law occurrence outcome populationlevel eg incidence COVID v imposition public health restrictions andor patient level eg characteristic people newly diagnosed v changes law Study Design Populationlevel cohorts Patientlevel characterisation Participants Populationlevel analysis include entire source population least  year data visibility available start study period Additional eligibility criterion could apply populationlevel disease epidemiology see above Stratification used case Differenceindifference study obtain control unimpacted counterfactual comparison Patientlevel analysis restricted newly diagnosed subjects using year washout potential additional eligibility see above Exposures least one public health measure regulatory action eg banning change use medicinal product intervention imposed known date time case Differenceindifference analyses affect known subpopulation another subpopulation affected intervention acting unimpacted counterfactual study period prespecified divided preexposure ie unimpacted time postexposure ie impacted calendar time Differenceindifference studies observed pre v postexposure change Exposed compared Unexposed subpopulation lag period intervention start postexposure study period could considered allow action impact study outcomes Outcomes following estimated prespecified study period including least  year interventions interest Populationbased incidence rate conditiongroup conditions time Populationbased prevalence conditiongroup condition time Differenceindifferences populationbased incidence prevalence conditiongroup conditions time exposed v unexposed population separately patient level two cohort newly diagnosed people studied namely diagnosed period unimpacted v intervention impacted following outcomes obtained compared cohorts Patientlevel characteristic amongst newly diagnosed v intervention Optional Patientlevel characteristic amongst prevalent case given dates v intervention Prognosis  progression prespecified outcome within prespecified time diagnosed v exposure interest Standard care description including n  receiving prespecified list medicines common combination among diagnosed v exposure interest Optional Standard care description including n  receiving prespecified list medicines common combination among prevalent case specified date v exposure interest Followup populationlevel analyses followup start prespecified calendar time point least  year proposed intervention continue least  year it patientlevel analyses followup go date diagnosis newly diagnosed cases prespecified date prevalent cases earliest loss followup end data availability death Analyses Incidence prevalence rates disease time estimated detailed section  available segmented regression method used estimate impact proposed interventions pre v postintervention changes trend populationlevel prevalence andor incidence Coefficients segmented regression reported quantify impact interventions incidence prevalence use together DurbinWatson residual diagnostic case autocorrelation ARIMAX model fitted instead segmented regression data permits differenceindifference studies parallel trend intervention identified requisite type study confirmed Differenceindifference model used subtract difference unexposed group exposed one whilst controlling time varying factors thus estimating causal effect intervention patientlevel analyses standardised mean difference covariates comparison new case diagnosed prevalent case pre v postintervention period obtained measure impact exposure profile new cases Study Type Trend analysis RMM effectiveness considered complex DUS require bespoke modelling intervention like risk minimization measure RMM completion population andor patientlevel DUS typically take form interrupted time series analyse impact regulatory action use medicine populationlevel eg incidence use v RMM andor patient level eg characteristic new drug user v RMM Study Design Populationlevel cohort New drug user cohort Participants Populationlevel analysis include entire source population least time typically  year data visibility available start study period Additional eligibility criterion could apply populationlevel DUS see above Patientlevel analysis restricted new prevalent user specified list medicines medicinal products specified time pointperiod using washout potential additional eligibility criterion considered see above Exposures least one RMM imposed known date time RMM or series RMMs main study exposureintervention analysis study period therefore prespecified divided ie unimpacted time ie impacted calendar time lag period publication communication RMM start postexposure study period could considered allow RMM impact study outcomes Outcomes following estimated prespecified study period including least  year RMM exposures interest Populationbased incidence rate use drugdrug class time Populationbased prevalence use drugdrug class time patient level two cohort new prevalent drug users studied namely initiated user treatment interest period unimpacted v RMM impacted following outcomes obtained compared cohorts New drug user cohorts patientlevel characteristic index date Optionally prevalent drug user cohorts patientlevel characteristic index date Followup populationlevel analyses followup start prespecified calendar time point least  year imposed RMM continue least  year it patientlevel analyses followup go date therapy initiation for new users prespecified date for prevalent users earliest loss followup end data availability death Patients might censored time discontinue treatment switch alternative therapy date RMM Analyses Incidence prevalence rates drugs use time estimated detailed section  available segmented regression method used estimate impact imposed RMMs populationbased pre v postintervention trend drugs use Coefficients segmented regression indicating difference trend period immediately intervention step change reported quantify formal test impact RMMs incidence prevalence use together DurbinWatson residual diagnostic case autocorrelation ARIMAX model fitted instead segmented regression data permits patientlevel analyses standardised mean difference covariates comparison newprevalent drug user preRMM v postRMM period obtained measure impact RMM profile new drug users Additionally measure patientlevel DUS provided stratified time therapy initiation pre post RMM Complex Studies Studies cannot rely electronic health care databases would require complex andor novel methodological work complex study design defined moment Quality Assurance Software Development Software Quality Assurance also called Software Testing Life Cycle process aim assure software doe supposed according Software Requirements Specification SRS code quality assurance process within DARWIN EU follow agile development method shown Figure  Figure  Agile software development method method continuously applied software lifecycle monitor improve quality process monitored Quality Assessment Lead interacts closely Product Owner contains following steps Plan Plan Phase agreed code require testing part prioritized next sprint Design design phase Software Specification Requirements SRS Test Plan created updated in following sprints SRS provides benchmark test planning since specifies function nonfunctional requirements situation expected applied in whom Test Plan living document get updated development sprints Develop develop step quality measure implemented code base get updated according Test Plan includes creation unit test etc Test quality control phase process software tested according plan ensure provides correct results ha cross platform compatibility stable efficient outcome test recorded taken account next sprint Issues identified flagged bug either immediately rectified case significant error eg incorrect application functionality providing false answers deemed enhancements fixed next development cycle package eg software requires much memory Deploy phase major minor software release created code kept development status improvement Quality software development focus  main themes  doe software produce correct results tested using small scale example units tests correct answer known  software run required platform without producing errors examined checking eg incorrect parameters platform difference both database management operating systems Last Updated  March  Disclaimer content website responsibility DARWIN EU Coordination Centre cannot interpreted reflecting view European Medicines Agency European Medicines Regulatory Network    European Medicines Agency right reserved Certain part licensed condition European Medicines Agency Data Research Memory Research Memory DARWIN EU Coordination Centre CC developing library store reusable study artefact concept set phenotype definitions need make artefact Findable Accessible Interoperable Reusable FAIR moment CC working library OMOPbased phenotype reused with without modifications conduct study DARWIN EU network DARWIN EU Cohort Knowledge base DECK Solid well defined algorithm necessary identify people set characteristic eg coded diagnosis recorded prescriptions dispensations specific medicine logic eg first diagnosis specific condition initiation specific therapy make part cohort use OMOP CDM enables generation review approval transportable cohort definition across network previously mapped data sources DARWIN EU Cohort Knowledge base DECK short compile transportable algorithm used identify cohort necessary conducting EMAcommissioned studies including user specific medicinal product drug utilisation studies people specific condition study descriptive epidemiology people newly diagnosed specific health outcome study drug safety DECK leverage existing knowledge compiled OHDSI community previous EHDEN studies previous studies including EMAcommissioned tenders existing preliminary version DECK collates large number clinical definition previously produced using previous studies possible andor necessary DARWIN EU study leverage validated algorithm DECK cumulative knowledge generated using DECK accelerate study conducted Years  also maximise reproducibility research reusing exact documented variation algorithm event time Last Updated  March  Disclaimer content website responsibility DARWIN EU Coordination Centre cannot interpreted reflecting view European Medicines Agency European Medicines Regulatory Network    European Medicines Agency right reserved Certain part licensed condition European Medicines Agency Data Studies Studies DARWIN EU Coordination Centre implement necessary service generate reliable evidence real world data EU Regulatory network Initially DARWIN EU provide service EMA National Competent Authorities NCAs Member States network expands DARWIN EU may perform study requested EMA behalf third party EU level health agency eg European Centre Disease Prevention Control ECDC health technology assessment body payers question raised partner EU Regulatory Network requiring additional evidence support regulatory decisionmaking EMA frame research question evaluate consultation Coordination Centre relevance feasibility interrogating network study Coordination Centre develop study protocol identify appropriate data source specific question obtain EMA approval perform conduct study data partners Following local governance procedure data partner need obtain mandatory institutional IRB andor ethic approval data partner receive run code database provide aggregated result Coordination Centre Coordination Centre check quality study data received data partner perform additional data analysis step interpretation Coordination Centre compile results responsible draft study report submit report EMA approval study DARWIN EU deliver grouped anticipated level complexity frequency Category Description OffTheShelf Studies mainly characterisation question executed generic protocol includes study disease epidemiology example estimation prevalence incidence health outcome defined time period population groups drug utilization study population patient level Complex Studies study requiring development customisation specific study designs protocols analytics phenotypes includes study safety effectiveness medicine vaccines Routine Repeated Analyses Routine analysis based OffTheShelf Complex Studies see above repeated prespecified regularity eg yearly Complex Studies Studies cannot rely electronic health care databases require complex andor novel methodological work study executed DARWIN EU Coordination Center registered  uptodate list studies search term DARWIN EU title study field list updated monthly basis Status Type EU PAS Register number Official Title Last Updated Finalised offtheshelf EUPAS  Finalised offtheshelf EUPAS  Finalised complex EUPAS  Finalised offtheshelf EUPAS  Ongoing offtheshelf EUPAS  Ongoing offtheshelf EUPAS  Ongoing complex EUPAS  Ongoing offtheshelf EUPAS  Ongoing offtheshelf EUPAS  Ongoing offtheshelf EUPAS  Ongoing offtheshelf EUPAS  Ongoing offtheshelf EUPAS  Ongoing offtheshelf EUPAS  Ongoing offtheshelf EUPAS  Ongoing Complex EUPAS  Ongoing offtheshelf EUPAS  Ongoing offtheshelf EUPAS  Last Updated  March  Disclaimer content website responsibility DARWIN EU Coordination Centre cannot interpreted reflecting view European Medicines Agency European Medicines Regulatory Network    European Medicines Agency right reserved Certain part licensed condition European Medicines Agency Data FAQs General General information DARWIN EU found menu FAQs receive EMA responsible providing leadership direction setting standard DARWIN EU contracting instructing overseeing Coordination Centre monitoring performance overall operation DARWIN EU overseen Management Pillar guidance Advisory Boards board composed Scientific Advisory Board Ethical Advisory Board Data Source Prioritisation Committee initiative also receives oversight DARWIN EU Advisory Board EMA read  present DARWIN EU CC provides service EMA National Competent Authorities NCAs Member States therefore receives study request EMA behalf organisations network expands DARWIN EU may perform study requested EMA behalf third party EU level health agency eg European Centre Disease Prevention Control ECDC health technology assessment body payers read DARWIN EU work deliver study described Catalogue Standard Data Analyses categorised Offtheshelf Complex Complex Routine Repeated read Studies published European Union Electronic Register PostAuthorisation Studies EU PAS Register access uptodate list study DARWIN EU ha produced search term DARWIN EU Title study field Otherwise check updated list study website following organisation contribute establishment operational phase Coordination Centre Fore information see  present necessity add additional subcontractor organisation help deliver requested services Erasmus University Medical Centre current contractor subcontractor already added tendering process get touch Coordination Centre email email address protected spambots need JavaScript enabled view itor  Joining Network interested joining network read process  FAQs process No considered candidate DP first step submit Expression Interest Yes unless duly justified case appropriate justification included information contained EoI primarily used purpose evaluating candidacy formally become DARWIN EU Data Partner access associated Data Protection Notice  Additionally providing consent response specific question EoI form potential DP agree EoI information used populate EU Metadata Catalogue EMA initiative help improve data discoverability transparency Catalogue intended public use read associated Data Protection Notice No continuously open call please bear mind cutoff date th April st October review selection No CC may contact clarify certain aspect datasets EoI invite initiate formal onboarding process latter successfully completed agreement signed DARWIN EU DP onboarding process consists several quality technical check ensure readiness DARWIN EU studies plus explanation term condition participation agreement legal provision apply relationship CC duration vary   months ordinarily No onboarding process ha successfully completed agreement CC ha signed question listed above get touch Coordination Centre email Disclaimer content website responsibility DARWIN EU Coordination Centre cannot interpreted reflecting view European Medicines Agency European Medicines Regulatory Network    European Medicines Agency right reserved Certain part licensed condition European Medicines Agency Data Contact DARWIN EU Coordination Centre represented Department Medical Informatics Erasmus MC Route Description Fields marked  required Type Question Please select one General Question Open Call Expression Interest Data Protection Name Email Subject Message Consent consent hereby give consent store process information provided form Data Protection Notice dataprotectionnotice hereby accept Enter captcha security code Send Email Send Email Reset PUBLIC TRANSPORT Metro ABC Alight Dijkzigt station follow sign Erasmus MC Bus  Alight Dijkzigt station follow sign Erasmus MC Tram  Alight Kievietslaan station Enter Westzeedijk parking garage Car direct vicinity Erasmus MC follow sign parking garages Parking Westzeedijk Westzeedijk   AA Rotterdam Parking Wytemaweg Wytemaweg   CN Rotterdam Route Description Coordination Center hosted Department Medical Informatics th floor NaBuilding Disclaimer content website responsibility DARWIN EU Coordination Centre cannot interpreted reflecting view European Medicines Agency European Medicines Regulatory Network    European Medicines Agency right reserved Certain part licensed condition European Medicines Agency Data AboutCoordination Centre Coordination Centre EMA working Erasmus University Medical Center Rotterdam to establish theDARWIN EUCoordination Centre support work build distributed data network conduct scientific study answer research question supporting regulatory decisionmaking EMAs scientific committee  maintain catalogue real world data source use regulatory context metadata DARWIN EU Coordination Centre key user future  contract establish Coordination Centre wa awarded Erasmus University Medical Center Rotterdam following call tender service provider published June  group Department Medical Informatics leading Establishment Operational Phase DARWIN EU Coordination Centre Organisational Structure DARWIN EU CC exists run study within data partner network overseen Study Network Operations pillars respectively pillar able execute study onboard Data Partners using tool such code protocols created Development pillar within infrastructure ha created Technology pillar Technology pillar also responsible producing necessary project resources website service desk overall operation DARWIN EU overseen Management pillar guidance Advisory Boards Leadership Erasmus MC Executive Director Technology Pillar Lead Erasmus MC Oxford University Deputy Director Development Pillar Lead Erasmus MC Deputy Director Study Operations Pillar Lead Synapse Research Management Partners Management Pillar Lead Erasmus MC Network Operations Pillar Lead Additional Members core team  Development Pillar Colead  MSc Analytics Team Colead  Study Operations Colead  Technology Pillar Colead  Management Pillar Colead  Management Team Lead addition large team data scientists epidemiologist programmer working Coordination Centre Erasmus MC subcontractors Contributing Organisations Organisation Department Medical Informatics Erasmus MC Description Erasmus University Medical Center largest eight university medical center Netherlands Department Medical Informatics chaired Prof dr ir Peter Rijnbeek interdisciplinary research group within Erasmus MC study new method acquiring representing processing managing data knowledge health care biomedical science ha developed land marking infrastructure software distributed analysis electronic health records Health Data Science research line Prof Rijnbeek leading  EHDEN mission group produce clinically actionable insight observational health data enabling datadriven healthcare Improved interoperability data necessary prerequisite mission Learn Organisation Clinical Investigation Translational Science NDORMS University Oxford Description Clinical Investigation Translational Science division Botnar Research Centre NDORMS University Oxford includes Clinical Trial Design Medical Statistics Health Data Science sections Health Data Science section led Prof Daniel PrietoAlhambra includes multidisciplinary team  staff student expertise data sciences engineering epidemiology real world evidence Learn at Organisation Synapse Research Management Partners Description Synapse firm specialized high quality management complex research development project biomedical sector Synapse partner national international organisations public private pharmaceutical biotechnology companies research institutes academia hospitals etc Synapse ha track record research project highly innovative open innovation public private partnerships large with several million Euros funding distributed built collaboration several institutions internationally oriented with broad expertise project funded European Commission Learn  Organisation Description IQVIA leading global provider advanced analytics technology solutions clinical research service health sector across globe IQVIA creates intelligent connection across aspect healthcare analytics transformative technology big data resource extensive domain expertise IQVIA delivers powerful insight speed agility enabling life science industry customer accelerate clinical development commercialization innovative medical treatment enabling government ass improve public health population management leading improved patient outcomes approximately  employees IQVIA conduct operation  countries Learn  Organisation Hyve Description Hyve company provides professional service open source software specialize field cancer genomics translational data warehousing real world data analytics research data management customer include majority top  pharmaceutical companies major academic medical center US Europe well biobanks registry patient organization throughout world Learn Organisation Odysseus Data Services Inc Description Odysseus established realworld evidence RWE solution provider enabling standardized systematic analytics observational data scale Odysseus providing customer Software Data Engineering Data Science solution supporting largescale RWE generation Odysseus active OHDSI contributor multiple key initiative working groups including design development OHDSI platform ATLASWebAPI ARACHNE ATHENA OMOP CDM standards curating maintaining OMOP standard vocabulary well development OHDSI analytical method HADES OHDSI distributed network research Odysseus created ARACHNE platform goal linking multiple distributed life science healthcare organization single network enable standardized federated analytics observational data Learn Data Partners CC ha set agreement growing list Data Partners create distributed network data sources information Data Partners found page Last Updated  May  Disclaimer content website responsibility DARWIN EU Coordination Centre cannot interpreted reflecting view European Medicines Agency European Medicines Regulatory Network    European Medicines Agency right reserved Certain part licensed condition European Medicines Agency Data AboutWho Involved involved DARWIN EU ha multiple actors     Data Partners DARWIN EU collaborates data partner help generate realworld evidence used scientific evaluation regulatory decisionmaking Data partner partner access raw data inhouse remotely ownership public contract thirdparty agreement commercial license Data partner enable DARWIN EU use data scientific study executing analytic packages provide analysis result DARWIN EU Coordination Centre accordance data protection governancerules information see page Coordination Centre ha key function DARWIN EU CC provides structure developing managing network data partners including training process study methods evaluating eligibility performing studies monitoring data quality CC also responsible implementing operating step  feasibility request study final delivery study report EMA result integrated within EU regulatory decision making process addition Coordination Centre responsible methodological development DARWIN EU directed instructed EMA interact relevant initiatives Erasmus University Medical Center Rotterdam wa selected contractor public tendering procedure published June  setup Coordination Centre EMA information see page European Medicines Agency responsible providing leadership direction setting standard DARWIN EU contracting instructing overseeing Coordination Centre monitoring performance question raised EU Medicines Regulatory Network requiring additional evidence support regulatory decisionmaking EMA coordinate definition research question define requesting body study objective possible study design option study population exposures outcome statistical measures information communicated Cordination Centre feasibility assessment Based feasibility assessment EMA consultation Cordination Centre decide relevance conducting study specify eligibility criterion database included identify relevant database define evidentiary standard applied study eg data quality EMA process result analysis report specific studies feeding result decisionmaking appropriate support establishment DARWIN EU ha set EMA EU Medicines Regulatory Network EU Medicines Regulatory Network includes EMA encompassing scientific committee working parties national competent authority NCAs Member States European Economic Area EEA European Commission operation DARWIN EU need additional realworld evidence identified within EU Medicines Regulatory Network support regulatory activity submitted discussed EMA Organisations Interactions EMA organisations institution project take place improve infrastructure methodological standard operational process DARWIN EU network interaction could take place with example EHDS DARWIN EU key user need fully integrated use service provided EHDS ongoing EU national project scope DARWIN EU relevant quality transformation maintenance analysis realworld datasets including European networking initiative EHDEN project European platform registry European Reference Networks ERNs ha established registry platform rare diseases ENCePP network integration continuously updating good methodological practice pharmacoepidemiology identification data source registration studies regulatory authority third countries learn experience integrate learning governance methodological aspects Last Updated  March  Disclaimer content website responsibility DARWIN EU Coordination Centre cannot interpreted reflecting view European Medicines Agency European Medicines Regulatory Network    European Medicines Agency right reserved Certain part licensed condition European Medicines Agency Data AboutPrinciples  Policies Principles  Policies Table content Data Protection DARWIN EU Coordination Center CC executes study distributed data network using federated approach analytical code shared data partner aggregated study result shared CC privacybydesign approach additional measure added example minimum cell count comply local governance rules data partner setup includes information procedure information study execution found  latest version Record Processing Activities ROPA found below information also see  Cookie Policy DARWIN EU Coordination Center websitewe use cooky enablethe technical functioning thiswebsiteIn addition consent it use cooky collect browsing experience website enables u tocollect anonymous statistic help u improve website services information see website Conflict Interest study analysis conducted DARWIN EU shall conducted accordance principle scientific independence set According ENCePP scientific independence mean that primary purpose study shall generate evidence potential scientific public health importance promote use medicinal product specific outcome design research shall aim minimising potential bias financial commercial institutional personal interest particular outcome study ie result interpretation level organisations initiating funding study coordinating study entity andor researchers conducting study shall influence decision scientific aspect study direction including data collection analysis interpretation dissemination study results relevant definition principle set shall also applied Related content Related document List item First published  EMA List item First published  Last Updated  March  Disclaimer content website responsibility DARWIN EU Coordination Centre cannot interpreted reflecting view European Medicines Agency European Medicines Regulatory Network    European Medicines Agency right reserved Certain part licensed condition European Medicines Agency Data AboutWebinars DARWIN EU multistakeholder information webinar Date  LocationOnline    Amsterdam time CET Event summary EMA organised multistakeholder information webinar to introduce DARWIN EU recently appointed Coordination Centre highlight opportunity collaboration answer stakeholder questions Video recording Documents Last Updated  March  Disclaimer content website responsibility DARWIN EU Coordination Centre cannot interpreted reflecting view European Medicines Agency European Medicines Regulatory Network    European Medicines Agency right reserved Certain part licensed condition European Medicines Agency Data Legal Notice Legal Notice Table content Information onThe DARWIN EU website subject disclaimer copyright limited reproduction notices Disclaimer website managed Erasmus University Medical Center Rotterdam hereinafter Coordination Centre CC behalf European Medicines Agency hereinafter EMA contract signed CC EMA see Official Journal  Coordination Centre maintains website enhancepublic accessto information activity performing behalf European Medicines Agency CCs goal keep information material timely accurate error brought attention CC try correct them CC EMA acceptno responsibility liabilitywhatsoever including limited to direct consequential loss damage might occur andor third party arising of connection with information site including information relating document may publish link to particular CC EMA shall held harmless from indemnified costs proceedings claims expense liability whatsoever arising breach legal natural person result representation warranty providing misrepresentation information CC provides is general nature intended address specific circumstance particular individual entity necessarily comprehensive complete accurate date sometimes linked external site CC ha control CC assumes responsibility amounting professional legal advice CCs goal minimise disruption caused technical errors However data information website may created structured file format errorfree CC EMA cannot guarantee service interrupted otherwise affected problems CC EMA accept responsibility whatsoever regard problem incurred result using website Copyright limited reproduction notice appearance content webpage subject copyrights whether EMA third party   European Medicines Agency right reserved Certain part licensed condition European Medicines Agency Information document made available DARWIN EU webpage public may reproduced andor distributed totally part irrespective mean andor format used provided DARWIN EUwebsite always acknowledged source material acknowledgement must included copy material Citations may made material without prior permission provided source always acknowledged However document copyright vest third party permission reproduction must obtained copyright holder DARWIN EU Trademark Logo DARWIN EU European Union figurative trademark owned European Medicines Agency EUTM no  Use trademark prohibited without prior written permission EMA Citing website cite material DARWIN EU website please list URL month year accessed it using following format DARWIN EU Expression InterestXLSXKB httpsdarwineuorgdataExpressionofInterestformvaxlsx  Links website CC encourages organisation individual create link website following conditions Links must used defamatory context Linked information must changed way Linked information darwineuorg displayed manner suggests endorsement commercial product service Linked information darwineuorg displayed alongside advertising Last Updated  March  Disclaimer content website responsibility DARWIN EU Coordination Centre cannot interpreted reflecting view European Medicines Agency European Medicines Regulatory Network    European Medicines Agency right reserved Certain part licensed condition European Medicines Agency Data Cookie Policy Cookie Policy Table content make website work properly DARWIN EU Coordination Centre CC place small data file called cooky device Website visitor decide whether tracked cookies delete cooky time cooky cookie small piece ofdatathat website store visitor computer mobile device DARWIN EU Website theDARWIN EU Coordination Centreuses cooky enablethe technical functioning thiswebsiteIn addition consent it use cooky collect browsing experience website enables u tocollectanonymous statisticsto help u improve website services Different type cookiesexist Firstparty cooky set website visiting website read them website might use firstparty cooky external service analyse people use site JRealtime Analytics see below Thirdparty cooky set stored different website manner outsidethe control site visiting Session cooky temporarily saved web browser enable website track navigation treated new user every time go page page aredeleted automatically close browser Persistent cooky saved computer longer deleted automatically close browser JRealtime Analytics cooky JRealtime Analytics tool running server monitor browsing experience website use evaluate websites effectiveness efficiency solely based native session cookie Joomlato collect statistics DARWIN EU Coordination Centreretains full control data collected native cookie storing dataon server platform enables protection personal data usersthanks feature deidentification ofIP addresses Consent collecting browsing experience register yourbrowsing experience using cooky areenabled open page visit website banner appears givesyou option accept eitherallcookies essential cookies accept essential cookies stop JRealtime Analytics accept cookies enable JRealtime Analytics make selection continue browse website cooky areenabled default Choosing accept essential cooky doe affect navigation experience website decide withdraw give consent enabling cooky time cookie popup remain visible bottom webpage change preference Data protection JRealtime Analytics JRealtime Analytics us cookiesto track following information visitors IP address deidentified Locationcountry region city approximate latitude longitude Date time visit Title page viewed URL page viewed URL page wa viewed prior current page Time visitorslocal time zone Duration visit page Links another websitethat clicked Time webpage generated server downloaded visitor Browser type Safari Chrome etc Operating system Window Mac etc Device type Desktop Laptop etc Restricted access information Onlyauthorised staff DARWIN EU Coordination Centre authorised access theanalytical report generated JRealtime Analytics report graphical representation item described above example visitor per country pie chart operating systems access reportsthrough administrative portal DARWIN EU Website Masking IP address JRealtime Analytics us anIP deidentification mechanismto automatically maska portion visitors IP address Thiseffectively makesit impossible identify particularvisitor using IP address statistical purposes city country origin determined full IP address stored aggregated anonymisation mask applied Visitor log DARWIN EU Coordination Centre store anonymised aggregated data indefinite period analysis purposes cooky website contains userinput cookies aresession cookies support user feedback featurethatallows youto rate usefulness websites page tell u more website doe use thirdparty cooky stored different website butit doe contain link audiovisual content website thatmay use cookies viewthis content need accept thespecific term condition external website includes cookie policies CC ha control cookie policy external websites view content external provider install anythirdparty cooky device Details thecookie policy websitesare provided cookie notice pages Do track option Do trackis browser function prevents website trackingvisitors enabled do track option browser JRealtime Analytics process browsing experience website number browser do track option Related content Last Updated  March  Disclaimer content website responsibility DARWIN EU Coordination Centre cannot interpreted reflecting view European Medicines Agency European Medicines Regulatory Network    European Medicines Agency right reserved Certain part licensed condition European Medicines Agency